aTyr Pharma Inc.

97 articles with aTyr Pharma Inc.

• aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

  6/26/2018

  aTyr Pharma Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced positive data from its Phase 1 clinical trial of ATYR1923, an immuno-modulatory therapeutic candidate with potentially broad therapeutic application in the treatment of interstitial lung diseases.

• 

  aTyr Pharma Slashes 30% of Employees as it Initiates Corporate Restructuring Following ORCA Failure

  5/14/2018

  Shares of San Diego-based aTyr Pharma are down nearly 20 percent this morning after the company announced a corporate restructuring plan that includes a 30 percent reduction of staff following failures of its preclinical ORCA program.

• aTyr Pharma Doses First Subjects in Phase I Trial of iMod.Fc (ATYR1923)

  11/27/2017

  This first-in-human, randomized, double-blind, placebo-controlled study is designed to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous iMod.Fc in healthy volunteers.

• aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

  11/15/2017

  Research and development expenses were $7.1 million and $10.4 million for the three months ended September 30, 2017 and 2016, respectively. T

• 

  aTyr Promotes CMO to CEO

  11/2/2017

  aTyr Pharma announced that today Sanjay Shukla, M.D., M.S., who joined aTyr Pharma as CMO in March 2016, will succeed John Mendlein, Ph.D., as President and CEO.

• aTyr Pharma To Present Final Data For Resolaris Phase Ib/II Trial In Patients With Early-Onset Facioscapulohumeral Muscular Dystrophy At The 22nd International Annual Congress Of The World Muscle Society

  9/27/2017

• aTyr Pharma, A US-Hong Kong Biotech, Announces $46 Million Private Placement

  8/29/2017

• San Diego's aTyr Pharma Nabs $45 Million Equity Financing

  8/28/2017

• aTyr Pharma Announces Second Quarter 2017 Operating Results And Provides An Update On Innovative Immunology Pipeline

  8/15/2017

• aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results

  8/11/2017

• aTyr Pharma Announces First Quarter 2017 Operating Results

  5/12/2017

• aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At The American Academy of Neurology 69th Annual Meeting

  4/24/2017

• aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At American Academy of Neurology 69th Annual Meeting

  4/24/2017

• aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial In Patients With Early Onset Facioscapulohumeral Muscular Dystrophy

  4/24/2017

• aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy

  4/24/2017

• aTyr Pharma Announces Appointment Of Timothy P. Coughlin To Its Board Of Directors

  4/11/2017

• aTyr Pharma Announces Appointment Of Timothy P. Coughlin To Its Board Of Directors

  4/11/2017

• aTyr Pharma Announces Appointment Of Jeffery S. Hatfield To Its Board Of Directors

  4/3/2017

• aTyr Pharma Announces Fourth Quarter And Year-End 2016 Operating Results

  3/17/2017

• aTyr Pharma Announces Issuance Of U.S. Patent That Extends Patent Protection Of Physiocrines Derived From 20 Out Of 20 Human tRNA Synthetases

  3/15/2017